Licensing agreement of ThioBridge™ signed with Abzena (AIM: ABZA)

OBI Pharma (‘OBI’, TPEx: 4174) has signed a licensing agreement and a master services and clinical supply agreement with Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group), a UK-based life sciences group that provides biopharmaceutical services and technologies. The licensing agreement introduces ThioBridge ™, a novel linker technology for Antibody Drug Conjugate. OBI will utilize […]

This article is password protected.

To view the content, please enter your password in the field below